• Users Online: 78
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 36  |  Issue : 4  |  Page : 380-386

Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study


1 Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan
2 Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan
3 Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
4 Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Higashihiroshima, Japan
5 Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
6 Department of Ophthalmology, Saitama Medical Centre, Jichi Medical University, Shimotsuke, Japan
7 Department of Ophthalmology, The University of Tokyo Hospital, Tokyo, Japan
8 Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
9 Department of Ophthalmology, Yodogawa Christian Hospital, Osaka, Japan
10 Centre for Ophthalmic Specialized Care; University of Lausanne, Lausanne, Switzerland

Correspondence Address:
Masaki Takeuchi
Department of Ophthalmology, National Defense Medical College, 3-2 Namiki, Tokorozawa City, Saitama, 359-8513
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sjopt.sjopt_204_22

Rights and Permissions

PURPOSE: We investigated the efficacy and safety of adalimumab (ADA) treatment for chronic recurrent Vogt-Koyanagi-Harada (VKH) patients with sunset glow fundus (SGF). METHODS: Medical records of 50 chronic recurrent VKH patients with SGF who received ADA treatment for more than 6 months were retrospectively reviewed. RESULTS: The mean age of chronic recurrent VKH patients with SGF was 55.9 ± 14.4 years, and the male/female ratio was 26/24. Before ADA treatment, the mean daily dose of systemic corticosteroids was 16.5 ± 12.7 mg, and 22 patients (44%) were under immunosuppressors. LogMAR visual acuity (VA), flare counts, subfoveal choroidal thickness (SFCT), indocyanine green angiography scores, and corticosteroid and cyclosporine doses were significantly reduced by ADA treatment at 6 months compared to baseline. Among all parameters, flare count was significantly related to LogMAR VA. LogMAR VA was significantly related to flare counts but not to SFCT nor to ICGA scores. ADA treatment was continued in 94%. CONCLUSION: ADA was shown to be effective in achieving remission of chronic recurrent VKH disease with SGF refractory to conventional treatments, and was generally well tolerated with few serious adverse events.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed182    
    Printed12    
    Emailed0    
    PDF Downloaded39    
    Comments [Add]    

Recommend this journal